Cardiovascular Systems (CSII) Prelim. Q1 Results Miss Expectations

Go back to Cardiovascular Systems (CSII) Prelim. Q1 Results Miss Expectations

BofA/Merrill Lynch Downgrades Cardiovascular Systems (CSII) to Underperform

October 8, 2015 7:45 AM EDT

BofA/Merrill Lynch downgraded Cardiovascular Systems (NASDAQ: CSII) from Buy to Underperform with a price target of $15.00.

For an analyst ratings summary and ratings history on Cardiovascular Systems click here. For more ratings news on Cardiovascular Systems click here.

Shares of Cardiovascular Systems closed at $16.63 yesterday.

... More

Needham & Company Downgrades Cardiovascular Systems (CSII) to Buy

October 8, 2015 7:37 AM EDT

Needham & Company downgraded Cardiovascular Systems (NASDAQ: CSII) from Strong Buy to Buy with a price target of $18.00 (from $37.00).

Analyst Mike Matson commented, "We are downgrading CSII to Buy from Strong Buy after last night's negative preannouncement. On one hand, we see... More

Leerink Partners Downgrades Cardiovascular Systems (CSII) to Market Perform

October 8, 2015 6:24 AM EDT

Leerink Partners downgraded Cardiovascular Systems (NASDAQ: CSII) from Outperform to Market Perform with a price target of $17.00 (from $45.00) after the company preannounced weaker-than-expected F1Q16 sales driven by another quarter of salesforce disruption.

Analyst Danielle Antalffy commented, "Clearly the salesforce transition... More